Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Dr. Alfred Sandrock, the man most closely associated with Biogen's controversial Alzheimer's disease therapy, Aduhelm, will retire at the end of the year.

Top Biogen Executive Announces Retirement as Aduhelm Rollout Stumbles

CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for VUMERITY® (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS). VUMERITY is a next-generation fumarate that offers the convenience of an oral medication with the established efficacy and well-characterized safety of TECFIDERA® (dimethyl fumarate). Globally, an estimated 2.8 million people live with MS, with more than 1 million people in Europe living with the disease.1 ,2

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

Biogen Inc said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer's disease drug Aduhelm, is leaving the company after a 23-year run.

Biogen's research chief Alfred Sandrock to retire

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that Alfred “Al” W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2021. A 23-year veteran of Biogen, Dr. Sandrock, 64, led the development of many of the Company's most important and transformational therapies in neurological diseases, including Tysabri® (natalizumab), Tecfidera® (dimethyl fumarate), Spinraza® (nusinersen), Plegridy® (peginterferon beta-1a) and Aduhelm™ (aducanumab-avwa). Dr. Sandrock served on Biogen's Executive Committee since 2015, as Head of Research & Development since October 2019, and as Chief Medical Officer from 2012 to 2020.

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that it has set an industry record as the most frequently recognized biotechnology company on the Dow Jones Sustainability World Index (DJSI World), earning recognition for the ninth consecutive year, more than any other biotechnology company. The acknowledgment highlights the company's longstanding leadership actions and transparency on environmental, social and governance (ESG) issues.

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.

Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm

​​​​​​Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:   Biogen Posts Just $300K Sales From Aduhelm In Q3, Though Earnings Beat Estimates.

Why Are Biogen Shares Gaining Today?

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM™ (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer's disease. Reductions in plasma p-tau181 were also correlated with a lowering of amyloid beta plaque. The pre-specified analysis of plasma samples was conducted by an independent lab, drawing from the two pivotal ADUHELM Phase 3 EMERGE and ENGAGE trials. The findings were presented today at the Clinical Trials on Alzheimer's Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts.

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease

Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD. The data were presented at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference.

Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial

TOKYO and CAMBRIDGE, Mass., Nov. 11, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). This presentation was made by Eisai at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference, November 9-12, 2021 in Boston, Massachusetts and virtually.

Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Cassava Sciences Inc

Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.

Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?

With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition. Companies like Roche Holdings AG (OTC: RHHBY) and Eli Lilly And Co (NYSE: LLY) are already lining up reviews for their own Alzheimer's candidates.

Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters

Annovis Bio

Anavex Life Sciences

Eli Lilly

Prothena

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

Amgen

Gilead Sciences

Incyte

Regeneron Pharmaceuticals

Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.

5 Buy-Rated Biotech Stocks to Bolster Your Portfolio

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q3 Earnings Releases?

Abbott Labs

Alnylam Pharmaceuticals

Pfizer

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.

The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present a variety of new data from its Alzheimer's disease product portfolio and clinical development pipeline at the upcoming annual Clinical Trials on Alzheimer's Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts. Biogen's contributions to the conference are driven in part by analyses from the largest clinical trial dataset in early Alzheimer's disease research. This includes over 3,000 patients in Phase 3 trials and approximately 1,700 patients in the ADUHELM (aducanumab-avwa) redosing trial, EMBARK.

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Aduhelm (aducanumab) sales got off to a very slow start in Q3.

Biogen's Long Aduhelm Game

Apple

Alibaba

Intel

Micron Technology

Walmart

As investors prepare for Halloween, the top six stocks that GuruFocus members are researching for the holidays are Intel Corp. ( INTC , Financial), Apple Inc. ( AAPL , Financial), Biogen Inc. ( BIIB , Financial), Alibaba Group Holding Ltd. ( BABA , Financial), Walmart Inc. ( WMT , Financial) and Micron Corp. ( MU , Financial) according to GuruFocus Virtual Baskets statistics.

GuruFocus Members Are Researching These Stocks for the Holidays

Aduhelm remains a big question mark for the company.

Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock

If history is any guide, there may be trouble ahead for shares of Biogen (NASDAQ:BIIB). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Will Chart Analysts Notice Bad Omen on Biogen's Chart

With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?

Should Biogen Investors Be Preparing for the Worst?

It's an exciting if turbulent, and rather cutthroat, time in the world of Alzheimer's drug research. In June, the FDA greenlit Biogen's.

Eli Lilly Pitches Alzheimer Drug to the FDA, Aiming to Leapfrog Biogen

Viatris

A screening of healthcare stocks in the S&P 500 reveals that investors may find plenty of upside in three members of the index, according to an article in Barron's. The analysis showed that Vertex Pharmaceuticals ( VRTX , Financial), Viatris Inc. ( VTRS , Financial) and Incyte Corp. ( INCY , Financial) all sell at deep discounts to price forecasts by Wall Street analysts.

There's Money to Be Made With Vertex, Viatris, Incyte and Biogen

Sure, Biogen beat analysts' estimates in Q3. But the company still has some serious challenges.

News for Biogen Stock (BIIB)